Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of limaprost tablets for degenerative lumbar spinal stenosis
ChiCTR2300076153Phase 4Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- May 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of limaprost in lumbar spinal stenosis (LSS) and degenerative lumbar spinal stenosis (LSS) (2 arms), sponsored by Peking University Third Hospital. Primary endpoints: Percent change from baseline in JOA subjective symptom score at 6 months, Percent change from baseline in Oswestry Disability Index at 6 months and 4 more. Started May 2023; status: recruiting.
02
Drugs
limaprost
03
Conditions
lumbar spinal stenosis (LSS)degenerative lumbar spinal stenosis (LSS)
Beyond the preview
Go deeper on ChiCTR2300076153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076153.